Skip to content
Disclosery

Paradigm Biocapital Advisors LP

Follow

13F filer, CIK 1855655, NEW YORK, NY

Paradigm Biocapital Advisors LP reported $2,183,397,711 across 28 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-15. Its ten largest share positions make up 76.41% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001855655-25-000007

Period
2025-03-31
Reported value
$2.18B
Holdings
28
Top 10 weight
76.41%
New
6
Sold out
6

Part of the filer group Paradigm Biocapital Advisors LP

  • Paradigm BioCapital Advisors GP LLC
  • Paradigm BioCapital International Fund Ltd.
  • Senai Asefaw, M.D.
How groups are built

Stakes and trades reported after 2025-03-31

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • OBX OBSIDIAN THERAPEUTICS INC: 13G 4,101,576 shares, 6.6% of the class, 13G filed 2026-10-05, 0001104659-26-113688Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MERUS N Vadded+1,679,777$70.7M
CYTKnew+858,664$34.5M
INSMnew+451,359$34.4M
MTSRnew+1,191,462$32.4M
COGTadded+4,046,243$24.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ARGXreduced-421,626-$250M
VERAexited-1,437,339-$60.8M
MLTXreduced-1,144,788-$44.7M
PLRXexited-3,197,050-$42.1M
TECXexited-485,105-$22.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001855655-25-000007, largest first. % of portfolio is the value over $2,172,397,711, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NUVLNUVALENT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,000,000 shares; 2024Q4: 5,363,379 shares; 2025Q1: 5,269,433 shares 5,269,433$374M17.2%-93,946Timeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,000,000 shares; 2024Q4: 4,371,601 shares; 2025Q1: 4,492,032 shares 4,492,032$295M13.56%+120,431Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,314,089 shares; 2024Q4: 6,553,111 shares; 2025Q1: 6,178,111 shares 6,178,111$218M10.06%-375,000Timeline
ONCBEONE MEDICINES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 200,336 shares; 2024Q4: 616,024 shares; 2025Q1: 666,024 shares 666,024$181M8.34%+50,000Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,454,917 shares; 2024Q4: 1,689,922 shares; 2025Q1: 3,369,699 shares 3,369,699$142M6.53%+1,679,777
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,440,445 shares; 2024Q4: 2,531,896 shares; 2025Q1: 2,610,197 shares 2,610,197$134M6.17%+78,301Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,789,172 shares; 2024Q4: 4,493,929 shares; 2025Q1: 4,394,556 shares 4,394,556$96.7M4.45%-99,373Timeline
JANXJANUX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,400,574 shares; 2024Q4: 3,515,986 shares; 2025Q1: 3,329,909 shares 3,329,909$89.9M4.14%-186,077Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,516,686 shares; 2024Q4: 1,910,761 shares; 2025Q1: 1,946,168 shares 1,946,168$65.3M3%+35,407Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 627,732 shares; 2024Q4: 1,422,787 shares; 2025Q1: 1,696,481 shares 1,696,481$64.1M2.95%+273,694Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,497,720 shares; 2024Q4: 1,497,720 shares; 2025Q1: 1,210,971 shares 1,210,971$60.1M2.77%-286,749Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,609,762 shares; 2024Q4: 4,917,412 shares; 2025Q1: 8,963,655 shares 8,963,655$53.7M2.47%+4,046,243Timeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 770,455 shares; 2025Q1: 1,511,932 shares 1,511,932$38.9M1.79%+741,477Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 701,817 shares; 2024Q4: 1,283,766 shares; 2025Q1: 961,707 shares 961,707$35.9M1.65%-322,059Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 480,374 shares; 2024Q4: 481,305 shares; 2025Q1: 59,679 shares 59,679$35.3M1.63%-421,626Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 858,664 shares 858,664$34.5M1.59%newTimeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 451,359 shares 451,359$34.4M1.59%newTimeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,267,581 shares; 2024Q4: 1,527,205 shares; 2025Q1: 2,127,205 shares 2,127,205$34.3M1.58%+600,0002026-09-24, 13G: 4,457,450 shares, 5.1% of the class, 13G filed 2026-10-01 Timeline
MTSRMETSERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,191,462 shares 1,191,462$32.4M1.49%newTimeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,895,689 shares; 2024Q4: 1,820,079 shares; 2025Q1: 2,095,079 shares 2,095,079$28.2M1.3%+275,000Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,503,600 shares; 2024Q4: 7,304,970 shares; 2025Q1: 6,741,172 shares 6,741,172$25.3M1.17%-563,798Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 931,480 shares; 2024Q4: 1,772,211 shares; 2025Q1: 627,423 shares 627,423$24.5M1.13%-1,144,788Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,465,334 shares 1,465,334$22.9M1.05%newTimeline
Y-mAbs Therapeutics IncY-mAbs Therapeutics IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,086,346 shares; 2024Q4: 4,236,346 shares; 2025Q1: 4,236,346 shares 4,236,346$18.8M0.86%0
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 10,668,141 shares; 2024Q4: 10,752,354 shares; 2025Q1: 10,802,354 shares 10,802,354$14.8M0.68%+50,000Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,314,018 shares 1,314,018$9.63M0.44%newTimeline
IMTXIMMATICS N.VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,904,862 shares; 2024Q4: 5,414,409 shares; 2025Q1: 1,907,108 shares 1,907,108$8.6M0.4%-3,507,301Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
EWTXEDGEWISE THERAPEUTICS INC COMcall500,000$11Mnew

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VERAVERA THERAPEUTICS INC1,437,339$60.8Mshares
PLRXPLIANT THERAPEUTICS INC3,197,050$42.1Mshares
TECXTECTONIC THERAPEUTIC INC485,105$22.4Mshares
SRRKSCHOLAR ROCK HLDG CORP400,000$17.3Mshares
ORKAORUKA THERAPEUTICS INC819,660$15.9Mshares
AGIOAGIOS PHARMACEUTICALS INC276,439$9.08Mshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001855655-25-000007 base2025-05-15acceptance time not in the bulk data set